Summary
This executive summary of the 2020 ACC/AHA valvular heart disease guideline synthesises evidence from a comprehensive literature review (2010–2020) to provide updated clinical recommendations for diagnosis and management. The guideline updates prior recommendations with new evidence regarding diagnostic approaches, surgical and catheter-based interventions, and medical therapies. The summary focuses on key recommendations whilst referring readers to the full guideline for detailed rationale, flow charts, and evidence tables.
Regional applicability
As a joint ACC/AHA guideline from major United States cardiology organisations, direct applicability to UK practice depends on alignment with NICE guidance and NHS standards. UK clinicians may use this as international best-practice reference, though localised adaptation to NHS pathways and drug formularies would be necessary.
Key measures
Clinical diagnostic and treatment recommendations based on systematic literature review of evidence from January 2010 to March 2020
Outcomes reported
The guideline provides updated recommendations for diagnosis and management of valvular heart disease, including diagnostic work-up, timing and choice of surgical and catheter interventions, and medical therapy options.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.